Patients with intertrochanteric fractures admitted to the emergency ward who took Ketorolac alone or in conjunction with magnesium sulphate infusion experienced remarkable pain reduction; however, the combination therapy produced better results, as elucidated from a randomized clinical trial. The purpose of the study was to compare the effectiveness and side effects of Ketorolac combined with placebo and Ketorolac combined with magnesium sulphate to relieve intertrochanteric fracture pain.

A total of 60 patients with intertrochanteric fractures were segregated into two groups: (A) Ketorolac (30 mg) with placebo (n = 30), and (B) Ketorolac (30 mg) + Magnesium sulphate (15 mg/kg) (n = 30). At baseline and 20, 40, and 60 minutes after the interventions, hemodynamic parameters, complications (nausea and vomiting), and pain score using the visual analogue scale (VAS) were measured. The groups' additional morphine sulphate needs were contrasted.
The two groups' demographic information was comparable.

Except for the baseline assessments, all the evaluations revealed remarkably decreased pain intensity in the magnesium sulfate/Ketorolac group. Regarding hemodynamic measurements and complaints of nausea and vomiting, the two groups did not vary. Even while there was no difference in the frequency of subsequent morphine sulphate needs across the groups, those receiving Ketorolac/placebo treatment had considerably larger morphine sulphate doses.  Additional studies are highly recommended.